Achaogen Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., March 15, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today reported financial results for the fourth quarter and year ended December 31, 2015, and also provided an update on its corporate and clinical development activities.

For full access, please click here.